Objectives: Today, metformin is considered to be the first-choice drug and is considered the gold standard for most people with type 2 diabetes. Metformin is the most commonly used diabetic medication used worldwide. Metformin use in patients with congestive heart failure, moderate chronic kidney disease, or chronic liver disease with hepatic impairment is associated with improvements in mortality. Research has shown that metformin also has a protective effect on endothelium by decreasing endothelial vascular reactivity. We hypothesize that metformin will decrease restenosis/reintervention rates in patients receiving lower extremity arterial stents.
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Methods: A retrospective study was performed of 187 patients from October 2012 to December 2015 who received an arterial stent in the superficial femoral artery and/or popliteal artery. Patients were further broken down into three groups: nondiabetic, diabetic not on metformin, and diabetic on metformin and compared against each other for duplex-based restenosis (>60%) rates, limb loss rates, and reintervention rates. Smoking status was also taken into account, and patients were classified as current, former, or nonsmokers. Postoperative duplex checks were performed 1 week after the procedure, then every 3 months for the first year after the procedure, followed by once every 6 months to check for patency. Fisher exact test, one-way analysis of variance, c 2 , and multivariate logistical analysis were performed for statistical analysis.
Results: The average length of follow-up was 13.3 6 9.6 months. Of the 50 patients who were on metformin and diabetic, 24 had no restenosis, 34 had no reintervention, 26 had restenosis, and 16 had reintervention. Of the 43 patients who were diabetic but not on metformin, 27 had no restenosis, 32 had no reintervention, 16 had restenosis, and 11 had reintervention. Of the 94 patients who did not have diabetes, 57 had no restenosis, 64 had no reintervention, 37 had restenosis, and 30 had reintervention. No patients experienced limb loss. There were no statistically significant differences between any of the three groups and their limb loss, restenosis, or reintervention rates. Patient smoking status also had no effect on outcomes.
Conclusions: Despite having multiple proven effects in improving certain clinical outcomes and a proven protective effect on endothelium by decreasing endothelial vascular reactivity, metformin does not appear to reduce restenosis or reintervention rates in patients receiving lower extremity arterial stents.
Author Disclosures: A. Alsheekh: Nothing to disclose; E. Ascher: Nothing to disclose; M. A. Goldstein: Nothing to disclose; A. Hingorani: Nothing to disclose; T. Izakovich: Nothing to disclose; P. Kibrik: Nothing to disclose; C. M. Monteleone: Nothing to disclose; J. Victory: Nothing to disclose. Objectives: Functional popliteal artery entrapment syndrome (FPAES) results from hypertrophied gastrocnemius, soleus, and/or plantaris muscles, without identifiable anatomic abnormality. Historically, FPAES has been managed with surgical myotomy. We reviewed the literature to evaluate the results of surgery along with a newer treatment (botulinum toxin A injection) for this rare form of claudication.
IP219. Functional Popliteal Artery Entrapment
Methods: A systematic literature search of PubMed, Cochrane, and Ovid yielded 1546 publications, Of these, 738 articles were eliminated based on abstract and title screening, 808 were assessed for eligibility, and 803 were excluded based on established exclusion criteria. Ultimately, data were extracted from five articles. From these we obtained the number of patients, demographic information, preoperative workup, surgical treatment details, follow-up imaging, and results of treatment.
Results: A total of 101 patients (61% female) were studied. Mean age was 27.5 years. Noninvasive testing revealed bilateral findings in 24%. Treatment involved surgical myotomy (93; four studies), and botulinum toxin injection (8; one study). Adjunctive vascular reconstruction was performed in eight of the surgical cases. FPAES patients who underwent surgical management were evaluated subjectively for symptomatic improvement of symptoms, and majority had duplex ultrasound studies in follow-up. Symptoms recurred in 8% (8 of 93), and 7.5% (7 of 93) had revision surgical procedures. Complications in the surgical management 
